NextCell Pharma AB (OSTO:NXTCL) E10: kr-1.15 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NXTCL NextCell Pharma AB OSTO:NXTCL
42 GF Score
Price kr1.01
GF Value kr0.90
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is NextCell Pharma AB E10?

NextCell Pharma AB OSTO:NXTCL -0.20% 42 E10 is kr-1.15 as of Dec. 2025. GuruFocus rates OSTO:NXTCL with a GF Score™ of 42/100 and a GF Value™ of kr0.90 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

NextCell Pharma AB's adjusted earnings per share data for the three months ended in Dec. 2025 was kr-0.120. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr-1.15 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-27), NextCell Pharma AB's current stock price is kr1.01. NextCell Pharma AB's E10 for the quarter that ended in Dec. 2025 was kr-1.15. NextCell Pharma AB's Shiller PE Ratio of today is .


NextCell Pharma AB  (OSTO:NXTCL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


NextCell Pharma AB E10 Related Terms


NextCell Pharma AB E10 Historical Data

* Premium members only.

The historical data trend for NextCell Pharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB E10 Chart

NextCell Pharma AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NextCell Pharma AB Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Dec25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.15

OSTO:NXTCL vs VRTX, REGN, RVMD: E10 Comparison

For the Biotechnology subindustry, NextCell Pharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCell Pharma AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where NextCell Pharma AB's Shiller PE Ratio falls into.


OSTO:NXTCL
42GF Score
NextCell Pharma AB OSTO:NXTCL
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NextCell Pharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NextCell Pharma AB's adjusted earnings per share data for the three months ended in Dec. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-0.12/133.3900*133.3900
=-0.120

Current CPI (Dec. 2025) = 133.3900.

NextCell Pharma AB Quarterly Data

per share eps CPI Adj_EPS
201508 0.000 99.829 0.000
201605 -0.449 100.914 -0.593
201608 -0.347 100.968 -0.458
201611 -0.363 101.517 -0.477
201702 -0.449 102.037 -0.587
201705 -0.482 102.679 -0.626
201708 -0.370 103.138 -0.479
201711 -0.251 103.413 -0.324
201802 -0.335 103.678 -0.431
201805 -0.240 104.632 -0.306
201808 -0.266 105.197 -0.337
201811 -0.340 105.443 -0.430
201902 -0.204 105.641 -0.258
201905 -0.267 106.895 -0.333
201908 -0.158 106.716 -0.197
201911 -0.142 107.345 -0.176
202002 -0.174 106.742 -0.217
202005 -0.332 106.882 -0.414
202008 -0.148 107.571 -0.184
202011 -0.182 107.549 -0.226
202102 -0.213 108.190 -0.263
202105 -0.150 108.838 -0.184
202108 -0.103 109.780 -0.125
202111 -0.150 111.069 -0.180
202202 -0.237 112.834 -0.280
202205 -0.213 116.746 -0.243
202208 -0.220 120.573 -0.243
202211 -0.205 123.803 -0.221
202302 -0.261 126.321 -0.276
202305 -0.320 128.034 -0.333
202308 -0.197 129.560 -0.203
202311 -0.280 130.958 -0.285
202402 -0.290 132.046 -0.293
202405 -0.260 132.818 -0.261
202408 -0.220 132.052 -0.222
202411 -0.110 133.000 -0.110
202502 -0.110 133.744 -0.110
202505 -0.140 133.064 -0.140
202508 -0.080 133.440 -0.080
202512 -0.120 133.390 -0.120

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr-1.15 mean?
NextCell Pharma AB (OSTO:NXTCL) has a E10 of kr-1.15 as of Dec. 2025. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on NextCell Pharma AB and its competitors.
Is NextCell Pharma AB's E10 too high?
NextCell Pharma AB's current E10 is kr-1.15. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's E10 compare to VRTX and REGN?
NextCell Pharma AB's E10 of kr-1.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on NextCell Pharma AB and its competitors. NextCell Pharma AB's current E10 is kr-1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (OSTO:NXTCL) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.90, compared to a current price of kr1.01 — trading 12.2% above its estimated fair value. The current E10 is kr-1.15. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For NextCell Pharma AB (OSTO:NXTCL), the current E10 is kr-1.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NextCell Pharma AB (OSTO:NXTCL) Overvalued in 2026?

Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued. The current stock price of kr1.01 is trading 12.2% above its estimated GF Value™ of kr0.90. GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.

Key valuation signals for OSTO:NXTCL:

  • E10: kr-1.15
  • GF Value™: kr0.90 vs. price of kr1.01 (12.2% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the OSTO:NXTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NextCell Pharma AB Business Description

Other Exchanges 65G:Germany
Address Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score

Get the complete analysis for OSTO:NXTCL

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.01
Price
kr0.90
GF Value